Index RUT
P/E -
EPS (ttm) -1.78
Insider Own 26.45%
Shs Outstand 34.71M
Perf Week -10.69%
Market Cap 81.48M
Forward P/E -
EPS next Y -1.26
Insider Trans 0.00%
Shs Float 25.61M
Perf Month -36.07%
Income -60.19M
PEG -
EPS next Q -0.35
Inst Own 49.88%
Short Float 5.38%
Perf Quarter -34.45%
Sales 55.16M
P/S 1.48
EPS this Y -48.32%
Inst Trans -2.85%
Short Ratio 5.95
Perf Half Y -62.56%
Book/sh 3.77
P/B 0.62
EPS next Y 25.06%
ROA -31.12%
Short Interest 1.38M
Perf Year -67.27%
Cash/sh 2.06
P/C 1.14
EPS next 5Y -
ROE -40.00%
52W Range 2.19 - 12.51
Perf YTD -79.14%
Dividend Est. -
P/FCF -
EPS past 5Y -31.19%
ROI -44.28%
52W High -81.29%
Beta 0.92
Dividend TTM -
Quick Ratio 3.54
Sales past 5Y 21.26%
Gross Margin 46.75%
52W Low 6.85%
ATR (14) 0.23
Dividend Ex-Date -
Current Ratio 4.24
EPS Y/Y TTM -46.79%
Oper. Margin -58.51%
RSI (14) 36.91
Volatility 8.17% 9.06%
Employees 230
Debt/Eq 0.05
Sales Y/Y TTM 16.08%
Profit Margin -109.11%
Recom 1.40
Target Price 5.67
Option/Short Yes / Yes
LT Debt/Eq 0.04
EPS Q/Q -285.32%
Payout -
Rel Volume 0.62
Prev Close 2.46
Sales Surprise -8.46%
EPS Surprise -196.40%
Sales Q/Q 17.32%
Earnings Nov 12 BMO
Avg Volume 231.73K
Price 2.34
SMA20 -14.16%
SMA50 -25.95%
SMA200 -52.89%
Trades
Volume 142,846
Change -4.88%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-13-24 Downgrade
Leerink Partners
Outperform → Market Perform
$12 → $4
Feb-07-23 Initiated
Stephens
Overweight
$14
Oct-15-21 Resumed
Cowen
Outperform
Jan-12-21 Initiated
William Blair
Outperform
Jan-12-21 Initiated
SVB Leerink
Outperform
$70
Jan-12-21 Initiated
Stifel
Buy
$65
Jan-12-21 Initiated
Cowen
Outperform
Nov-13-24 02:10AM
Nov-12-24 08:15AM
07:00AM
Nov-11-24 07:21AM
Nov-04-24 07:00AM
07:00AM
Loading…
Oct-22-24 07:00AM
Oct-09-24 05:02PM
Sep-06-24 07:00AM
Aug-06-24 08:20AM
07:00AM
Jul-30-24 10:01AM
07:00AM
Jul-23-24 07:00AM
Jun-25-24 07:00AM
Jun-18-24 07:00AM
03:24AM
Loading…
Jun-07-24 03:24AM
May-15-24 07:00AM
May-14-24 09:55AM
May-09-24 09:35AM
May-01-24 08:49AM
03:09AM
12:08AM
(Thomson Reuters StreetEvents)
Apr-30-24 11:53AM
09:35AM
08:55AM
07:45AM
07:30AM
Apr-23-24 07:00AM
Mar-12-24 07:00AM
Mar-07-24 12:02PM
07:33AM
Loading…
Mar-05-24 07:33AM
07:00AM
Feb-29-24 07:00AM
Feb-22-24 07:00AM
Feb-20-24 07:00AM
Feb-02-24 11:01PM
Dec-28-23 12:00PM
Dec-27-23 10:30AM
Dec-22-23 01:01PM
Dec-19-23 09:55AM
Dec-18-23 05:34AM
Nov-14-23 07:00AM
Nov-09-23 03:37PM
Nov-07-23 08:14AM
07:00AM
Nov-06-23 04:30PM
Oct-31-23 07:00AM
Oct-24-23 04:30PM
07:00AM
Sep-26-23 07:00AM
Sep-18-23 07:00AM
Sep-15-23 07:00AM
Aug-26-23 07:50AM
Aug-08-23 09:15AM
07:00AM
Aug-07-23 07:00AM
Jul-31-23 07:00AM
Jul-25-23 07:00AM
Jul-16-23 08:42AM
Jul-13-23 05:42AM
May-30-23 07:00AM
May-23-23 09:54AM
07:00AM
May-09-23 08:25AM
07:00AM
May-04-23 07:00AM
Apr-26-23 07:00AM
Apr-25-23 07:00AM
Apr-18-23 11:14AM
Mar-08-23 02:22AM
(Thomson Reuters StreetEvents)
Mar-07-23 08:25AM
07:00AM
Feb-27-23 06:05PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Feb-07-23 01:37PM
Feb-06-23 05:16AM
Jan-17-23 07:00AM
Dec-29-22 06:02AM
Dec-07-22 07:00AM
Nov-16-22 06:24AM
Nov-14-22 11:44AM
10:05AM
07:00AM
Nov-10-22 07:00AM
Nov-09-22 07:00AM
Nov-02-22 07:00AM
Oct-19-22 07:00AM
Oct-12-22 05:00PM
Sep-29-22 07:50AM
Aug-09-22 04:00PM
08:45AM
07:30AM
07:00AM
Jul-27-22 07:00AM
Jul-25-22 07:21AM
Jul-19-22 07:00AM
Jun-13-22 04:22PM
Jun-02-22 07:00AM
May-26-22 07:00AM
908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Brown Christopher D. Chief Product Officer Aug 07 '24 Option Exercise 1.58 6,328 9,998 891,322 Aug 08 05:01 PM Eisenberg Marcia Director Jun 07 '24 Option Exercise 0.00 682 0 6,816 Jun 10 04:13 PM Knopp Kevin J. President and CEO May 13 '24 Buy 6.42 10,000 64,200 508,981 May 13 04:42 PM Knopp Kevin J. President and CEO May 10 '24 Buy 5.77 10,000 57,700 498,981 May 10 06:36 PM Knopp Kevin J. President and CEO May 09 '24 Buy 5.83 10,000 58,300 488,981 May 09 04:34 PM Knopp Kevin J. President and CEO May 08 '24 Buy 5.72 10,000 57,200 478,981 May 08 09:31 PM Knopp Kevin J. President and CEO May 07 '24 Buy 5.60 10,000 56,000 468,981 May 07 06:07 PM Knopp Kevin J. President and CEO Apr 16 '24 Option Exercise 1.75 47,000 82,250 458,981 Apr 16 04:11 PM Brown Christopher D. Chief Product Officer Apr 01 '24 Option Exercise 1.75 3,600 6,300 884,994 Apr 02 04:06 PM Griffith Joseph H. IV Chief Financial Officer Mar 26 '24 Option Exercise 1.58 8,437 13,330 93,437 Mar 27 04:16 PM Griffith Joseph H. IV Chief Financial Officer Feb 02 '24 Sale 7.09 9,711 68,873 80,000 Feb 02 07:10 PM Griffith Joseph H. IV Chief Financial Officer Feb 01 '24 Sale 7.00 5,698 39,892 89,711 Feb 02 07:10 PM Turner Michael S. Chief Legal & Admin Officer Feb 01 '24 Sale 6.99 5,232 36,559 9,105 Feb 02 04:40 PM Knopp Kevin J. President and CEO Feb 01 '24 Sale 7.00 9,071 63,461 411,981 Feb 02 04:39 PM Brown Christopher D. Chief Product Officer Feb 01 '24 Sale 7.01 3,957 27,730 886,394 Feb 02 04:37 PM Griffith Joseph H. IV Chief Financial Officer Dec 28 '23 Sale 12.08 6,000 72,480 80,000 Jan 02 05:01 PM Griffith Joseph H. IV Chief Financial Officer Dec 19 '23 Sale 9.08 5,580 50,666 86,000 Dec 21 04:47 PM Brown Christopher D. Chief Product Officer Dec 21 '23 Sale 9.12 7,370 67,214 877,905 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 19 '23 Sale 9.08 7,395 67,147 890,510 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 20 '23 Sale 9.10 5,235 47,638 885,275 Dec 21 04:46 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite